Mumbai-headquartered Lupin Limited has informed that the company launched Suprax 400 mg tablets (Cefixime USP) in the US market. The product is a line extension of Lupin’s flagship anti-infective Suprax in an oral suspension form.

Suprax® 400 mg tablets will help company to increase its share in the $450-million antibiotic market for the treatment of urinary tract infections. It will also extend the use of Suprax® to the patient population including children of the age of 12 yrs and above.

The Suprax-brand basket now includes Suprax (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml) and Suprax® 400 mg tablets (Cefixime USP).

Recently, Lupin Ltd. entered into the gynaecology segment and aims to tap 5% of the market share in the segment over the next two years, while maintaining its focus on lifestyle segment. The company in the next two years is eyeing 5% market share in the gynaecology segment. It has formed a separate division called Lupin Femina to manage the gynaecology division.